Patients undergoing ADHD medication titration lack structured daily tracking tools to distinguish routine adjustment symptoms from severe side effects, leading to unflagged adverse reactions and delayed dosage optimization.
Patients undergoing ADHD medication titration struggle to effectively track, judge, and timely report medication side effects and efficacy to their prescribers.
What do you wish you’d tracked during ADHD medication titration?
What do you wish you’d tracked during ADHD medication titration?
Patients starting or adjusting ADHD medications who need to log daily efficacy and side effect severity for prescriber reviews.
Patients report unstructured tracking leading to unflagged severe side effects and uncertainty distinguishing normal adjustment from critical symptoms.
Purpose-built exclusively for ADHD titration cadences and prescriber reporting, replacing generic habit trackers with clinically useful titration trends.
A mobile-first symptom and efficacy tracking app designed specifically for ADHD titration protocols that provides daily micro-check-ins, baseline normative symptom context, and 1-click clinical report summaries for prescribers.
Patients experiencing severe side effects or delayed prescription adjustments face high distress and extended private clinic fees, making $10/mo a small cost to ensure rapid, effective titration.
“Track daily side effects and export prescriber-ready titration logs in 60 seconds.”
A mobile-first symptom and efficacy tracking app designed specifically for ADHD titration protocols that provides daily micro-check-ins, baseline normative symptom context, and 1-click clinical report summaries for prescribers.
Target online ADHD patient communities (r/ADHD, r/ADHDthriving, UK NHS Shared Care groups) and partner with private ADHD assessment clinics.
Users may forget to log daily data when symptoms worsen or routines shift, undercutting report utility.
Misinterpretation of symptom guidance could lead patients to alter doses without consulting prescribers.
Titration is inherently temporary (2-4 months), requiring continuous low-cost user acquisition.
Run an Investment Memo to get a structured Go / No-Go verdict, competitor landscape, unit economics, and a 90-day validation roadmap for this opportunity.
Generate an investment memoThis idea scores in the upper-middle range of opportunities surfaced by MonetScope, with a validation sub-score of 7/10 against 2 independently sourced evidence signals. A "promising" rating usually indicates a real pain has been detected and discussed in the open, but the pipeline did not find enough signal to flag it as urgent or high-frequency. These opportunities can still produce excellent businesses — they often correspond to "boring" problems that established players have ignored — but the founder should expect a longer customer-development cycle to confirm willingness to pay.
It sits at the intersection of "data-management", "healthcare", "mobile-app", which makes it relevant to a specific subset of founders rather than a generic horizontal opportunity. SaaS opportunities at this stage tend to win on the strength of their initial wedge — a single workflow that the target user runs every week, where the existing solution is either spreadsheets, a clunky incumbent feature, or a manual process they hate. The build cost is moderate; the distribution cost is everything. The MonetScope pipeline surfaces this category alongside other saas signals, which is why it appears here rather than in a generic "trending ideas" feed.
Scores are derived from real forum discussions across Reddit, Hacker News and X, weighted by evidence volume and signal quality. How scoring works
MonetScope does not generate ideas from a language model's imagination. Every opportunity on this site is anchored to specific source posts and comments from real public discussions — typically on Reddit, Hacker News, or X — where actual users describe the pain in their own words. The AI's role is structuring, scoring, and grouping those signals into a navigable opportunity, not inventing the problem.
MonetScope's spider pipeline runs continuously and surfaces opportunities as new evidence accumulates. The "Updated" date in the header reflects the most recent re-scoring of this specific opportunity. Most saas opportunities visible in the public catalog draw from discussions in the last 30-60 days; older signals are de-prioritized because user pain shifts faster than most founders assume.
Overall score is a composite across six dimensions — pain, urgency, willingness to pay, market size, defensibility, and execution ease — designed to give a single number for triage. Validation score is narrower: it asks "how cleanly does the same signal repeat across independent sources?" An opportunity can score high on overall but lower on validation when one or two large discussions dominate the evidence; conversely, validation can be high on a smaller-overall idea where the signal is consistent but the addressable market is modest.
